Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315640 · ClinicalTrials.gov registry record · Phase 2
Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation
A Phase 2 study of Eye Diseases, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 12
- Study locations
NCT00315640: Completed Phase 2 study of Eye Diseases, sponsored by Alcon Research.
NCT00315640 is a Phase 2 study of Eye Diseases that has completed, run by Alcon Research. The registered enrollment target is 70 participants, below the 741,300-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 12 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00315640, a Phase 2 study of Eye Diseases, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of anecortave acetate depot when administered for the treatment of elevated IOP following treatment with steroids.
Conditions Studied
Interventions
- DRUG Anecortave Acetate Sterile Suspension, 60 mg/mL
- OTHER Anecortave Acetate Vehicle
- DRUG Anecortave Acetate Sterile Suspension, 6 mg/mL
- DRUG Anecortave Acetate Suspension Depot, 30 mg/mL
Study Locations (12)
Other
- San Paulo - São Paulo
- Budapest - Budapest
- Padova - Padua
- Amsterdam - Amsterdam
- Bayamon - Bayamón
- Barcelona - Barcelona
- Newcastle upon Tyne - Newcastle upon Tyne
Florida
- Jacksonville - Jacksonville
- Miami - Miami
Texas
- - Fort Worth
- Houston - Houston
Michigan
- Detroit - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2005-12 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00315640 record still lists
NCT00315640 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 741,300-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Eye Diseases appearing as the primary indexed condition, and to 4 interventions - of which Anecortave Acetate Sterile Suspension, 60 mg/mL is the first listed.
NCT00315640 lists 12 locations in 4 states (Other, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT00315640 about?
NCT00315640 is a clinical study titled "Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation". The purpose of this study is to evaluate the safety and efficacy of anecortave acetate depot when administered for the treatment of elevated IOP following treatment with steroids.
What is the current status of trial NCT00315640?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2005-12. Estimated completion is 2009-07.
What conditions does trial NCT00315640 study?
This clinical trial studies the following conditions: Eye Diseases.
What interventions are being tested in trial NCT00315640?
The interventions under investigation include: Anecortave Acetate Sterile Suspension, 60 mg/mL (DRUG), Anecortave Acetate Vehicle (OTHER), Anecortave Acetate Sterile Suspension, 6 mg/mL (DRUG), Anecortave Acetate Suspension Depot, 30 mg/mL (DRUG).
Who is sponsoring clinical trial NCT00315640?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00315640 being conducted?
This trial has 12 study locations across Florida, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00315640's enrollment target sits among peer trials
70 15th of 27 higher than 12 of 27 other Eye Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eye Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
COMPLETED · Phase 2
-
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia